A detailed history of Bridgeway Capital Management, LLC transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 255,000 shares of CLSD stock, worth $252,450. This represents 0.01% of its overall portfolio holdings.

Number of Shares
255,000
Previous 130,000 96.15%
Holding current value
$252,450
Previous $169,000 91.12%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.93 - $1.35 $116,250 - $168,750
125,000 Added 96.15%
255,000 $323,000
Q2 2024

Aug 14, 2024

SELL
$1.08 - $1.58 $216 - $316
-200 Reduced 0.15%
130,000 $169,000
Q1 2024

May 15, 2024

SELL
$1.2 - $2.02 $54,480 - $91,708
-45,400 Reduced 25.85%
130,200 $199,000
Q3 2023

Nov 14, 2023

SELL
$0.82 - $1.27 $85,280 - $132,080
-104,000 Reduced 37.2%
175,600 $152,000
Q2 2023

Aug 14, 2023

SELL
$0.97 - $1.48 $11,640 - $17,760
-12,000 Reduced 4.12%
279,600 $313,000
Q1 2023

May 15, 2023

SELL
$0.93 - $1.66 $23,250 - $41,500
-25,000 Reduced 7.9%
291,600 $303,000
Q2 2021

Aug 16, 2021

BUY
$2.32 - $5.38 $92,800 - $215,200
40,000 Added 14.46%
316,600 $1.54 Million
Q1 2021

May 17, 2021

BUY
$2.24 - $4.25 $207,424 - $393,550
92,600 Added 50.33%
276,600 $683,000
Q2 2020

Aug 14, 2020

BUY
$1.55 - $2.41 $145,700 - $226,540
94,000 Added 104.44%
184,000 $346,000
Q1 2019

May 15, 2019

SELL
$1.1 - $1.74 $54,120 - $85,608
-49,200 Reduced 35.34%
90,000 $124,000
Q3 2018

Nov 13, 2018

BUY
$6.03 - $11.24 $391,950 - $730,600
65,000 Added 87.6%
139,200 $856,000
Q2 2018

Aug 14, 2018

SELL
$8.91 - $14.54 $337,689 - $551,066
-37,900 Reduced 33.81%
74,200 $793,000
Q3 2017

Nov 14, 2017

BUY
$6.73 - $8.74 $754,433 - $979,754
112,100
112,100 $980,000

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $59.6M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.